JP5291089B2 - エリスロポエチンと顆粒球コロニー刺激因子とを組み合わせてなる医薬及び同医薬の製造におけるエリスロポエチン及び顆粒球コロニー刺激因子の使用方法 - Google Patents

エリスロポエチンと顆粒球コロニー刺激因子とを組み合わせてなる医薬及び同医薬の製造におけるエリスロポエチン及び顆粒球コロニー刺激因子の使用方法 Download PDF

Info

Publication number
JP5291089B2
JP5291089B2 JP2010504887A JP2010504887A JP5291089B2 JP 5291089 B2 JP5291089 B2 JP 5291089B2 JP 2010504887 A JP2010504887 A JP 2010504887A JP 2010504887 A JP2010504887 A JP 2010504887A JP 5291089 B2 JP5291089 B2 JP 5291089B2
Authority
JP
Japan
Prior art keywords
epo
csf
erythropoietin
treated
rats
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2010504887A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010526049A (ja
JP2010526049A5 (enExample
Inventor
リ、ハン
シュウ、ウォイ−チャン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Academia Sinica
Original Assignee
Academia Sinica
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Academia Sinica filed Critical Academia Sinica
Publication of JP2010526049A publication Critical patent/JP2010526049A/ja
Publication of JP2010526049A5 publication Critical patent/JP2010526049A5/ja
Application granted granted Critical
Publication of JP5291089B2 publication Critical patent/JP5291089B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2010504887A 2007-02-07 2008-02-07 エリスロポエチンと顆粒球コロニー刺激因子とを組み合わせてなる医薬及び同医薬の製造におけるエリスロポエチン及び顆粒球コロニー刺激因子の使用方法 Expired - Fee Related JP5291089B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/703,578 2007-02-07
US11/703,578 US7618938B2 (en) 2007-02-07 2007-02-07 Treating cerebrovascular diseases with erythropoietin and granulocyte-colony stimulating factor jointly
PCT/IB2008/000740 WO2009122227A2 (en) 2007-02-07 2008-02-07 Treating cerebrovascular diseases with erythropoietin and granulocyte-colony stimulating factor jointly

Publications (3)

Publication Number Publication Date
JP2010526049A JP2010526049A (ja) 2010-07-29
JP2010526049A5 JP2010526049A5 (enExample) 2011-03-24
JP5291089B2 true JP5291089B2 (ja) 2013-09-18

Family

ID=39676682

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010504887A Expired - Fee Related JP5291089B2 (ja) 2007-02-07 2008-02-07 エリスロポエチンと顆粒球コロニー刺激因子とを組み合わせてなる医薬及び同医薬の製造におけるエリスロポエチン及び顆粒球コロニー刺激因子の使用方法

Country Status (5)

Country Link
US (1) US7618938B2 (enExample)
EP (1) EP2139510B1 (enExample)
JP (1) JP5291089B2 (enExample)
TW (1) TWI327473B (enExample)
WO (1) WO2009122227A2 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1019082B2 (en) * 1997-10-02 2008-06-04 Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E.V. Use of a colony stimulating factor (csf) for enhancing collateral growth of collateral arteries and/or other arteries from preexisting arteriolar connections
AU2012225784B2 (en) 2011-03-04 2016-03-17 The Regents Of The University Of California Locally released growth factors to mediate motor recovery after stroke
US20160015786A1 (en) * 2013-03-01 2016-01-21 Mater Medical Research Institute Limited Mobilizing agents and uses therefor
US20210179721A1 (en) * 2017-11-29 2021-06-17 Csl Limited Method of treating or preventing ischemia-reperfusion injury

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU229475B1 (en) * 2001-12-06 2014-01-28 Fibrogen Methods of increasing endogenous erythropoietin (epo)
US7785601B2 (en) * 2002-12-31 2010-08-31 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors
US7220407B2 (en) * 2003-10-27 2007-05-22 Amgen Inc. G-CSF therapy as an adjunct to reperfusion therapy in the treatment of acute myocardial infarction
AU2005306894B2 (en) * 2004-11-05 2011-11-24 Northwestern University Use of SCF and G-CSF in the treatment of cerebral ischemia and neurological disorders

Also Published As

Publication number Publication date
TWI327473B (en) 2010-07-21
JP2010526049A (ja) 2010-07-29
EP2139510B1 (en) 2015-10-14
EP2139510A4 (en) 2012-04-04
US7618938B2 (en) 2009-11-17
EP2139510A2 (en) 2010-01-06
US20080188407A1 (en) 2008-08-07
WO2009122227A3 (en) 2010-03-11
TW200833352A (en) 2008-08-16
WO2009122227A2 (en) 2009-10-08

Similar Documents

Publication Publication Date Title
Arcasoy The non‐haematopoietic biological effects of erythropoietin
Micheli et al. VEGF-A/VEGFR-1 signalling and chemotherapy-induced neuropathic pain: therapeutic potential of a novel anti-VEGFR-1 monoclonal antibody
Yang et al. Heparin-binding epidermal growth factor-like growth factor and mesenchymal stem cells act synergistically to prevent experimental necrotizing enterocolitis
Lanfranconi et al. Growth factors in ischemic stroke
Wei et al. Transplantation of hypoxia preconditioned bone marrow mesenchymal stem cells enhances angiogenesis and neurogenesis after cerebral ischemia in rats
Calvo et al. Neuregulin-ErbB signaling promotes microglial proliferation and chemotaxis contributing to microgliosis and pain after peripheral nerve injury
Seyedsadr et al. Inactivation of sphingosine-1-phosphate receptor 2 (S1PR2) decreases demyelination and enhances remyelination in animal models of multiple sclerosis
Togbe et al. Both functional LTβ receptor and TNF receptor 2 are required for the development of experimental cerebral malaria
Fuchigami et al. Restoration of adult neurogenesis by intranasal administration of gangliosides GD3 and GM1 in the olfactory bulb of A53T alpha-synuclein-expressing Parkinson’s-disease model mice
EA032345B1 (ru) Способ лечения рака с использованием кофермента q10
Liu et al. Granulocyte colony-stimulating factor activating HIF-1α acts synergistically with erythropoietin to promote tissue plasticity
KR101909906B1 (ko) 비강 투여를 통한 뇌졸중 치료용 조성물
JP2010526049A (ja) エリスロポエチンおよび顆粒球コロニー刺激因子の併用による脳血管疾患の治療
JP2005528362A (ja) 血管新生の調節法
Lin et al. PACAP38/PAC1 signaling induces bone marrow-derived cells homing to ischemic brain
EA032569B1 (ru) Применение декстрансульфата, имеющего среднюю молекулярную массу mот 4500 до 7500 да, для индуцирования ангиогенеза у субъекта
US20230321152A1 (en) Cytokine storm suppressor, method for using cytokine storm suppressor and screening method
Kakehata et al. Therapeutic potentials of an artificial oxygen-carrier, liposome-encapsulated hemoglobin, for ischemia/reperfusion-induced cerebral dysfunction in rats
US20240189395A1 (en) Compositions, systems, and methods for treating or reducing hypoxia-ischemia induced brain damage and neurobehavioral dysfunction in neonates
JP6818358B2 (ja) 神経系血管バリアーの機能回復剤及び神経系疾患治療剤
Xing et al. Induced pluripotent stem cell-derived endothelial cells attenuate lipopolysaccharide-induced acute lung injury
Naito et al. Administration of granulocyte colony-stimulating factor facilitates the regenerative process of injured mice skeletal muscle via the activation of Akt/GSK3αβ signals
US20140323409A1 (en) Apotransferrin for the treatment of brain stroke
WO2025179292A1 (en) Compositions, systems, and methods for treating or reducing hypoxia-ischemia induced brain damage and neurobehavioral dysfunction in neonates
GB2568928A (en) Neuroprotective composition, preparation process thereof and medical uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110202

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110202

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20120112

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121030

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130130

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130412

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130514

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130606

R150 Certificate of patent or registration of utility model

Ref document number: 5291089

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees